Testosteronology Society adds diabetes guidance for testosterone care

The Testosteronology Society has released new member-only guidelines to help clinicians assess and manage diabetes, prediabetes and insulin resistance in patients receiving testosterone or androgen therapy. The guidance is meant to connect metabolic risk with hormone care and give providers a broader framework for treatment decisions.

Why it matters: - Patients receiving testosterone or other androgens often also have obesity, insulin resistance, prediabetes, diabetes, cardiovascular risk, kidney disease and sleep disorders. - The new guidance is designed to help clinicians treat those issues together instead of separately. - The Society says the goal is to raise the standard of care for complex patients receiving hormone therapy.

What happened: - The Testosteronology Society released new Diabetes Diagnosis and Management Guidelines on July 28, 2026. - The guidelines focus on patients receiving testosterone or other androgen therapies. - The resource is available only to Society members through the Guidelines & Resources library. - The Society also pointed readers to the new guidelines and Society membership and education programs.

The details: - The guidelines cover HbA1C interpretation, blood glucose monitoring, diabetes risk assessment, diagnostic testing and treatment considerations. - The clinical framework also addresses prediabetes, type 2 diabetes, type 1 diabetes and Latent Autoimmune Diabetes in Adults. - The resource includes insulin resistance, fasting insulin and C-peptide testing. - The guidance addresses Male Obesity-Associated Secondary Hypogonadism and hypercortisolism with severe metabolic dysfunction. - The document covers medications that may contribute to hyperglycemia. - The guidance recommends laboratory testing and ongoing monitoring. - The resource also includes nutrition, physical activity, sleep and behavioral support. - The guidelines discuss diabetes medications and treatment considerations. - The framework includes cardiovascular, kidney and metabolic risk management. - The Society says the guidance applies current diabetes recommendations specifically to patients receiving testosterone and other androgen therapies.

Between the lines: - The release shows the Society is trying to define Testosteronology as a broader clinical field, not just hormone prescribing. - The multidisciplinary format suggests the organization wants clinicians to think across endocrine, metabolic, cardiovascular, renal and mental health factors. - The member-only structure also turns the guidelines into part of the Society’s education and retention strategy.

What's next: - The Society says the guidelines are part of a broader effort to build deeper educational and clinical foundations for Testosteronology. - Members also get access to the Testosteronology Professional Education Program, which covers testosterone therapy, androgen health, laboratory interpretation, metabolic health, cardiovascular considerations, sexual health, women’s hormone care, anabolic steroids and related systems. - Healthcare professionals are invited to join the Society to access the new materials and education offerings.

The bottom line: - Testosteronology Society is using diabetes care to expand its case for hormone treatment that accounts for the full metabolic picture.